RNAi firm Dicerna Pharmaceuticals to be acquired for $3.3B

Dicerna Pharmaceuticals Inc., the Lexington-based firm focused on ribonucleic acid interference (RNAi) drugs, has agreed to be acquired by Denmark’s Novo Nordisk A/S for $3.3 billion in cash.